Search
Skip to Search Results- 2Berry, Tanya R
- 2Veldhoen, Richard
- 2Wallin, L.
- 1Aburahess, Salah
- 1Akhtar-Danesh, N.
- 1Akuamoah Boateng, Maxwell
- 33Graduate and Postdoctoral Studies (GPS), Faculty of
- 33Graduate and Postdoctoral Studies (GPS), Faculty of/Theses and Dissertations
- 4Nursing, Faculty of
- 3Nursing, Faculty of/Health Systems
- 3Kinesiology, Sport, and Recreation, Faculty of
- 2Nursing, Faculty of/Health Equity
-
2011
Squires, J.E., Estabrooks, C., Gustavsson, P., Wallin, L.
Background: Interventions that have a better than random chance of increasing nurses' use of research are important to the delivery of quality patient care. However, few reports exist of successful research utilization in nursing interventions. Systematic identification and evaluation of...
-
Fall 2020
The mammalian transient receptor potential (TRP) channels, composed of six subfamilies and 28 members, play crucial roles in sensory physiology and malfunctions of TRP channels cause channelopathies. High-resolution structures of TRP channels indicate conformational arrangements showing physical...
-
Investigation of BCL-2 interacting killer (BIK) as a breast cancer biomarker and its role in failed apoptosis
DownloadSpring 2019
Breast cancer is the number one cause of cancer-associated deaths in women worldwide. It can be broadly classified into estrogen receptor (ER) positive or -negative subtypes which form the basis of treatment. Despite the therapeutic advancements, more than half a million women annually succumb to...
-
Investigation of the BRCT repeats in human hereditary breast cancer and DNA damage response
DownloadFall 2009
The C-terminal region of breast cancer susceptibility gene 1 (BRCA1) contains a pair of tandem BRCT repeats that are critical for the tumour suppressor function of BRCA1. BRCT repeats are present in a large of number of proteins that are implicated in the cellular response to DNA damage. A subset...
-
Living at-Risk for Hereditary Breast Cancer: The Experiences of at-Risk Unaffected Women Who Live in Families Where a BRCA Gene Mutation Could Not be Found
DownloadSpring 2016
Harmful mutations in the breast cancer 1 and 2 genes (BRCA1/2) and other breast cancer susceptibility genes are thought to account for less than 30% of familial breast cancer cases. Many affected women (those with a personal history of breast and/or ovarian cancer) who undergo BRCA1/2 genetic...
-
MOLECULAR AND PHENOTYPIC CHARACTERIZATION OF DISTINCT BREAST CANCER CELL SUBPOPULATIONS PURIFIED USING A SOX2 REGULATORY REGION 2 TRANSCRIPTION ACTIVITY REPORTER
DownloadFall 2015
Sex-determining Region Y-box 2 (Sox2) is a transcription factor integral to the maintenance of pluripotency in embryonic stem cells. In recent years, Sox2 expression has been detected and implicated in the pathogenesis of breast and other cancers. Clinically, Sox2 expression has been associated...
-
2016-12-09
Winter, Philip, Wang, Xumin, Mackey, John R. , Lee, John C. , Wong, Gane Ka-Shu, Ghosh, Sunita, Patterson, Jordan, Zhang, Hangxiao, Wang, Weiwei, Tuszynski, Jack A. , Katsetos, Christos D., Graham, Kathryn, Luduena, Richard F.
Tubulin is the target for very widely used anti-tumor drugs, including Vinca alkaloids, taxanes, and epothilones, which are an important component of chemotherapy in breast cancer and other malignancies. Paclitaxel and other tubulin-targeting drugs bind to the β subunit of tubulin, which is a...
-
Fall 2010
In Canada, obesity and associated chronic diseases disproportionately affect First Nations children. The objectives of this research were to assess obesity, physical activity, and perceptions of lifestyle behaviors in Cree First Nations children (5-12 years) in one Alberta reserve community....
-
Fall 2011
Taxanes are used for the treatment of breast, ovarian, and lung cancer. Unfortunately, taxane based therapy—the current treatment for metastatic breast cancer—has substantial shortcomings including myelosupression, neurotoxicity, and frequently acquired resistance. Our present understanding of...
-
Fall 2011
Taxanes are used for the treatment of breast, ovarian, and lung cancer. Unfortunately, taxane based therapy—the current treatment for metastatic breast cancer—has substantial shortcomings including myelosupression, neurotoxicity, and frequently acquired resistance. Our present understanding of...